WntResearch presents an interim report with Foxy-5 phase 1-data
WntResearch today announces that an interim report with Foxy-5 phase 1 clinical data will be released on the company homepage in the evening of November 5.
As previously communicated WntResearch will present an abstract with results from their studies on Foxy-5 at a major international congress on anti-cancer drug development in Boston on the 6th of November.*
To ensure that all stakeholders have access to the same information at the same time, the company announces that an interim report with data from the phase 1 clinical study will be published on their homepage (www.wntresearch.com). The presentation will be published in the evening of November 5 and placed under the heading ‘Investor & media’, subheading ‘Events & presentations’.
CEO, Nils Brünner says: “We are happy to now being able to present a first preliminary report of our data from the phase 1 study on Foxy-5, both to the scientific community and our stock owners. Meanwhile we are still working on the final and complete report of the phase 1 study, which will be presented subsequently. We are currently also busy initiating the phase 1b study.”
*The joint meeting of AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, in Boston, Massachusetts, USA.
For additional information please contact:
Nils Brünner, CEO
Telephone: + 45 2614 4708
WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.